NCT07167433View on ClinicalTrials.gov

Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology

RecruitingOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

September 19, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Ovarian Cancer
Trial Locations (1)

Unknown

RECRUITING

Research Site, Porto Alegre

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT07167433 - Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology | Biotech Hunter | Biotech Hunter